Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
NEW YORK, March 20, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased NantHealth, Inc. (NASDAQ:NH) securities (1) pursuant and/or traceable to the Company’s Initial Public Offering on or about June 1, 2016; and/or (2) between June 1, 2016 and March 6, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/nanthealth-inc-nh. There is no cost or obligation to you.
According to the complaint, during the class period the Company made false and/or misleading statements and/or failed to disclose that: (1) Company founder Patrick Soon-Shiong had donated funds through nonprofit organizations to the University of Utah for the purpose of funneling those funds back into NantHealth; (2) as such, the Company and Soon-Shiong participated in the violation of federal tax laws—exposing the Company to possible civil and criminal liability; (3) the Company improperly recorded orders received from the University of Utah as GPS Cancer test orders; and (4) that, as a result, the Company reported false and inflated GPS Cancer order figures for the third quarter of 2016.
If you suffered a loss in NantHealth you have until May 8, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/nanthealth-inc-nh.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
